These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1958399)

  • 1. Immunologic impairment after long-term remission in splenectomized patients with Hodgkin's disease.
    Loven D; Pick AI; Weiss H; Duczyminer-Kahana M; Lurie H
    Acta Oncol; 1991; 30(6):763-5. PubMed ID: 1958399
    [No Abstract]   [Full Text] [Related]  

  • 2. [Proportions and absolute count of T- and B-lymphocytes in peripheral blood and their blastic transformation induced by mitogens in splenectomized and non-splenectomized patients with Hodgkin's disease].
    Pluzańska A
    Acta Haematol Pol; 1978; 9(1):37-44. PubMed ID: 307325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long term effects of splenectomy on the immune-status of Hodgkin's disease patients depending on the modality of treatment (author's transl)].
    Schaadt M; Diehl V; Kalden JR; Schmidt N; Laskewitz E
    Med Klin; 1978 Oct; 73(40):1381-8. PubMed ID: 309061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term influence of splenectomy on immune functions in patients with Hodgkin's disease.
    Björkholm M; Askergren J; Holm G; Mellstedt H
    Scand J Haematol; 1980 Jan; 24(1):87-94. PubMed ID: 6966069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of the changes in immune status following radiotherapy for Hodgkin's disease.
    van Rijswijk RE; Sybesma JP; Kater L
    Cancer; 1984 Jan; 53(1):62-9. PubMed ID: 6690004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of splenectomy upon immunologic reactivity of patients with Hodgkin's disease.
    Rogan-Grgas J; Milas L; Hauptmann E; Nola P; Kolarić K; Maricić Z; Malenica B
    Tumori; 1981 Dec; 67(6):539-47. PubMed ID: 6977906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunity in Hodgkin's disease: status after 5 years' remission.
    Hancock BW; Bruce L; Whitham MD; Dunsmore IR; Ward AM; Richmond J
    Br J Cancer; 1982 Oct; 46(4):593-600. PubMed ID: 7138765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ecotaxis: the principle and its application to the study of Hodgkin's disease.
    Sousa MD; Yang M; Lopes-Corrales E; Tan C; Hansen JA; Dupont B; Good RA
    Clin Exp Immunol; 1977 Jan; 27(1):143-51. PubMed ID: 300302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increase of T lymphocytes in the spleen in Hodgkin's disease.
    Kaur J; Spiers AS; Catovsky D; Galton DA
    Lancet; 1974 Oct; 2(7884):800-2. PubMed ID: 4138221
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of radiochemotherapy and splenectomy on lymphoid subclasses in patients with Hodgkin's lymphoma in complete remission].
    Leoni P; Montroni M; Montillo M; Salvi A; Centurioni R; Fanciulli E
    G Clin Med; 1981 Oct; 62(10):685-92. PubMed ID: 6977469
    [No Abstract]   [Full Text] [Related]  

  • 11. The influence of splenectomy on cellular immunologic parameters in Hodgkin's disease.
    Wagener DJ; Geestman E; Borgonjen A; Haanen C
    Cancer; 1976 May; 37(5):2212-9. PubMed ID: 130968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.
    Steele R; Han T
    Cancer; 1978 Jul; 42(1):133-9. PubMed ID: 667791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B and T lymphocytes in Hodgkin's disease. Analysis at diagnosis and following therapy.
    Gajl-Peczalska KJ; Bloomfield CD; Sosin H; Kersey JH
    Clin Exp Immunol; 1976 Jan; 23(1):47-55. PubMed ID: 1083318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphocyte subpopulations in Hodgkin's disease and non-Hodgkin's lymphoma and the effects of radiotherapy.
    Balasem AN; Barker CR
    Clin Radiol; 1984 Sep; 35(5):353-7. PubMed ID: 6236011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immune profile in patients with Hodgkin's disease in long-term remission after cytostatic chemotherapy].
    Nagel GA; Pietra CD; Hartmann D; Rosenthal M; Albrecht R; Obrist R; Obrecht P
    Schweiz Med Wochenschr; 1979 Jan; 109(2):45-51. PubMed ID: 311514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased risk of breast cancer in splenectomized patients undergoing radiation therapy for Hodgkin's disease.
    Chung CT; Bogart JA; Adams JF; Sagerman RH; Numann PJ; Tassiopoulos A; Duggan DB
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(2):405-9. PubMed ID: 9069314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunity in Hodgkin's lymphoma].
    Danieli G; Montroni M; Leoni P; Magelli L; Totti S
    G Clin Med; 1975; 56(1):39-56. PubMed ID: 770222
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: Lymphocytes in spleen in Hodgkin's disease.
    Grifoni V; Del Giacco GS; Manconi PE; Tognella S; Mantovani G
    Lancet; 1975 Feb; 1(7902):332-3. PubMed ID: 46472
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic factors in Hodgkin's disease. II. Role of the lymphocyte defect.
    Björkholm M; Holm G; Mellstedt H; Johansson B; Killander D; Sunblad R; Söderberg G
    Scand J Haematol; 1978 Apr; 20(4):306-18. PubMed ID: 653310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persisting lymphocyte deficiences during remission in Hodgkin's disease.
    Björkholm M; Holm G; Mellstedt H
    Clin Exp Immunol; 1977 Jun; 28(3):389-93. PubMed ID: 302164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.